Pyxis Oncology is an immuno-oncology company focused on developing novel therapies to help patients defeat difficult to treat cancers. Built on the ground-breaking research of Dr. Thomas Gajewski, Pyxis is pursuing promising novel targets derived from the latest insights into the tumor microenvironment. Pyxis has generated preclinical data on these targets and is developing a pipeline of novel antibodies with the potential to help new patient populations not currently served by today's immunotherapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/17/19 | $22,000,000 | Series A |
Agent Capital Ipsen John Flavin Leaps by Bayer  Longwood Fund | undisclosed |
| 03/30/21 | $152,000,000 | Series B |
Acuta Capital Partners Arix Bioscience BVF Partners Cormorant Asset Management HBM Healthcare Investments Janus Henderson Investors Perceptive Advisors Pfizer Venture Investments RA Capital Management Ridgeback Capital Management RTW Investments Tekla Capital Management | undisclosed |
